NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis → The only AI company you should be looking at (From Behind the Markets) (Ad) Free SAVA Stock Alerts $21.28 -0.01 (-0.05%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$21.01▼$21.5850-Day Range$18.44▼$26.4152-Week Range$12.32▼$32.10Volume454,808 shsAverage Volume712,431 shsMarket Capitalization$919.72 millionP/E RatioN/ADividend YieldN/APrice Target$124.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside482.7% Upside$124.00 Price TargetShort InterestBearish28.91% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.25Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.01) to $1.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.64 out of 5 starsMedical Sector284th out of 947 stocksPharmaceutical Preparations Industry134th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $124.00, Cassava Sciences has a forecasted upside of 482.7% from its current price of $21.28.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted28.91% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 3.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 2.9 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Cassava Sciences this week, compared to 4 articles on an average week.Search Interest32 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.MarketBeat Follows15 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 650% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Cassava Sciences is held by insiders.Percentage Held by InstitutionsOnly 27.19% of the stock of Cassava Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($2.01) to $1.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesMarch 18, 2024 | ca.finance.yahoo.comSAVA Apr 2024 20.500 putMarch 17, 2024 | stockhouse.comROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVAMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 17, 2024 | seekingalpha.comCassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?March 16, 2024 | finance.yahoo.comSAVA Mar 2024 19.500 putMarch 15, 2024 | finance.yahoo.comSAVA Mar 2024 11.000 putMarch 14, 2024 | finance.yahoo.comSAVA Mar 2024 17.500 callMarch 14, 2024 | stockhouse.comUPCOMING SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!March 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 12, 2024 | finance.yahoo.comSAVA Jan 2025 2.500 callMarch 12, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaMarch 12, 2024 | finance.yahoo.comSAVA Aug 2024 12.500 callMarch 12, 2024 | msn.comBoeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: 5 Stocks Capturing Investors’ Attention TodayMarch 12, 2024 | benzinga.comAlzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection ReportMarch 11, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SciencesMarch 11, 2024 | msn.comCassava Sciences again under scrutiny over Alzheimer's drug researchMarch 11, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVAMarch 11, 2024 | finance.yahoo.comSAVA Apr 2024 17.500 callMarch 11, 2024 | msn.comCassava is money spinner – Minister, NnajiMarch 10, 2024 | finance.yahoo.comSAVA Mar 2024 17.000 callMarch 10, 2024 | finance.yahoo.comSAVA Mar 2024 22.000 callMarch 8, 2024 | ca.finance.yahoo.comSAVA Mar 2024 20.500 putMarch 7, 2024 | uk.finance.yahoo.comSAVA Mar 2024 21.500 callMarch 6, 2024 | stockhouse.comCassava Sciences Announces Virtual Presentation at the AD/PD(TM) 2024 International ConferenceMarch 6, 2024 | finance.yahoo.comBullish Cassava Sciences Insiders Loaded Up On US$3.12m Of StockMarch 5, 2024 | stockhouse.comSAVA SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!March 4, 2024 | prnewswire.comROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVASee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2023Today3/18/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees26Year FoundedN/APrice Target and Rating Average Stock Price Target$124.00 High Stock Price Target$124.00 Low Stock Price Target$124.00 Potential Upside/Downside+482.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.53% Return on Assets-52.58% Debt Debt-to-Equity RatioN/A Current Ratio9.13 Quick Ratio9.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book6.53Miscellaneous Outstanding Shares43,220,000Free Float39,335,000Market Cap$919.72 million OptionableOptionable Beta-0.42 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.11MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $426.61kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $457.64kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $400kDr. George ThorntonSenior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsLiquidiaNASDAQ:LQDAPliant TherapeuticsNASDAQ:PLRXInnovivaNASDAQ:INVAABIVAX Société AnonymeNASDAQ:ABVXORIC PharmaceuticalsNASDAQ:ORICView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 56,060 shares on 3/11/2024Ownership: 5.379%Goldman Sachs Group Inc.Bought 108,456 shares on 3/1/2024Ownership: 0.383%Virtu Financial LLCBought 26,824 shares on 2/26/2024Ownership: 0.116%Cable Car Capital LLCBought 53,500 shares on 2/20/2024Ownership: 0.127%Price T Rowe Associates Inc. MDBought 2,282 shares on 2/16/2024Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price target for 2024? 1 equities research analysts have issued 12 month target prices for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they anticipate the company's stock price to reach $124.00 in the next year. This suggests a possible upside of 482.7% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2024? Cassava Sciences' stock was trading at $22.51 on January 1st, 2024. Since then, SAVA stock has decreased by 5.5% and is now trading at $21.28. View the best growth stocks for 2024 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings results on Monday, May, 1st. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences shares split before market open on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly created shares were payable to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.51%), Vanguard Group Inc. (5.38%), Gallacher Capital Management LLC (1.38%), Northern Trust Corp (0.92%), Charles Schwab Investment Management Inc. (0.73%) and Nuveen Asset Management LLC (0.66%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAVA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our Partners8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.